The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.
about
Radiomics: extracting more information from medical images using advanced feature analysisPrognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-AnalysisCharacterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancerCorrelation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer.Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.Intratumoral Heterogeneous F-18 Fluorodeoxyglucose Uptake Corresponds with Glucose Transporter-1 and Ki-67 Expression in a Case of Krukenberg Tumor: Localization of Intratumoral Hypermetabolic Focus by Fused PET/MR ImageMaximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy.PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidenceMolecular imaging of metastatic potential.The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas.Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumorsEvaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studiesNoninvasive Evaluation of Metabolic Tumor Volume in Lewis Lung Carcinoma Tumor-Bearing C57BL/6 Mice with Micro-PET and the Radiotracers 18F-Alfatide and 18F-FDG: A Comparative Analysis.(18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer.Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical ImplicationsBrain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopyClinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer.Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography, computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with pathologically positive neck lymph nodeAssociation Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma.Non-small cell lung cancer evaluated with quantitative contrast-enhanced CT and PET-CT: net enhancement and standardized uptake values are related to tumour size and histology.FDG PET/CT and mediastinal nodal metastasis detection in stage T1 non-small cell lung cancer: prognostic implications.Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer.Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterizationIn vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.A systemic review of PET and biology in lung cancerIndependent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.18[F]FDG-PET/CT is a useful molecular marker in evaluating tumour aggressiveness: a revised understanding of an in-vivo FDG-PET imaging that alludes the alteration of cancer biology.Prognostic and predictive factors in resected non-small-cell lung cancer.Nitroimidazole derivatives: a patent review of US 2014/0141084 A1.Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer.Ursolic acid sensitizes radioresistant NSCLC cells expressing HIF-1α through reducing endogenous GSH and inhibiting HIF-1α.FDG-PET/CT predicts survival and lung metastasis of hypopharyngeal cancer in a multi-institutional retrospective study.Assessment of Aggressiveness of Breast Cancer Using Simultaneous 18F-FDG-PET and DCE-MRI: Preliminary Observation.FDG and Beyond.
P2860
Q23760733-C72E7757-DCFE-4CBC-BDA5-6944FA71AF35Q26771327-179FD3F9-09C4-42DE-A7FC-7BF283F38E25Q27304358-49FE8109-BDBE-41CE-A797-E69F63B6FF46Q27314809-57937164-3118-4468-A294-93BCEEA03C30Q30419853-6910AADB-4D4B-45D8-A334-3ADF400F5751Q33579714-E23B525D-2368-4A15-87D3-B5E3DD7A9AE6Q33704453-B22107D0-B1BF-4718-989E-BD46E916B979Q33750851-4EDB69BE-75A2-4AA7-8485-2D3A2147BD17Q33818999-0FB57BB7-F784-48CD-97F6-95E5F7722B5AQ33917943-F006EE45-B9EF-43CA-B31A-67FDC774D777Q33968359-D34BB674-3310-4E73-892C-7442C04A55D2Q33973367-CA057470-278D-4ACF-A2E2-739D2A1BA1BDQ34243313-1573F82A-CDB9-4E4D-B2F4-9EA94EF997C0Q35103263-F242802C-0876-43BF-BBEA-41ABB8381220Q35151263-0D8FB129-5CA6-4DBC-A317-670ABB4E7053Q35767740-EAB0641B-FC2A-4089-A33B-11A99E67A8B4Q35870847-9260827E-738F-45BF-8A91-EC546E798029Q35915703-FE6980FE-8D1E-4003-AB8D-67027BCA3FD8Q35929573-60E7E37A-B04C-4990-BF13-6C25B5B3456CQ36195043-762D8161-F8D7-478B-A33D-AA1E31424996Q36410337-AB4A9681-A40D-47EC-A475-072C4761D01BQ36537056-C34E2AED-B939-44F8-ABF1-54E83E5977ABQ36604985-61A69F7E-D7E9-4E5E-9323-9A1C9E39AC3CQ36773472-E8E87E52-3AAF-4C71-AE1F-4025D239BC54Q37063199-35047920-EEC8-47E3-90FA-71AFC5851B99Q37178855-15467C8E-4A38-4411-B6FC-3DCD7530FBB4Q37426436-34372F30-D18D-481E-B848-2560569B9D00Q37440346-1A6AD9F0-1453-4004-896F-526E53923516Q37581964-7AF53587-406C-44AA-8940-076CCBC353F4Q37706118-B2580A51-14B8-402B-AAFC-F595C927F3B6Q37929599-50DED985-4F55-4FD6-8E0F-1FD8563F8977Q38014317-2D1694FA-BEF0-4799-8BE8-A9332C8D32F9Q38025952-F5F4F594-6D26-45AF-BE1D-AF868C21E34DQ38089884-FD606FA7-CF3D-48A4-9F40-2E42B92660E8Q38340260-83B072F7-2AEC-40CE-81BF-D3E08CE1D604Q38580483-F97A39F0-4D2E-485A-9464-F8027A53BA32Q38709677-DB6A1A00-B734-4E5F-A524-53AA2A6606A5Q38805585-9D7B1CC9-81D4-4545-AD75-53B0AD2DD98AQ38866273-3AB62507-5525-41DC-8888-FA5970F8FAD3Q38869438-11ACD198-8E34-4571-8204-95498E9A8277
P2860
The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
The maximum uptake of (18)F-de ...... in non-small cell lung cancer.
@en
The maximum uptake of (18)F-de ...... in non-small cell lung cancer.
@nl
type
label
The maximum uptake of (18)F-de ...... in non-small cell lung cancer.
@en
The maximum uptake of (18)F-de ...... in non-small cell lung cancer.
@nl
prefLabel
The maximum uptake of (18)F-de ...... in non-small cell lung cancer.
@en
The maximum uptake of (18)F-de ...... in non-small cell lung cancer.
@nl
P2093
P1476
The maximum uptake of (18)F-de ...... in non-small cell lung cancer.
@en
P2093
Cary Dehing-Oberije
Christophe Dooms
Dennis Rupa
Erik Verbeken
Johan Vansteenkiste
Monique Hochstenbag
Philippe Lambin
Robert Jan van Suylen
Sigrid Stroobants
Silvia Pastorekova
P304
P356
10.1016/J.EJCA.2007.03.027
P577
2007-05-23T00:00:00Z